{  
   "name":"Claim Categories",
   "children":[  
      {  
         "name":"Antibody",
         "color":"green",
         "children":[  
            {  
               "name":"Sequence",
               "color":"green",
               "children":[  
                  {  
                     "name":"Variable Region",
                     "color":"green",
                     "claimReason":"“... with a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3 ...”",
                     "indClaim":"<p>[IC]</p>12. An isolated human antibody, or an antigen-binding portion thereof, with a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8, and with a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11.",
                     "depClaim":"<p>[DC]</p>13. The isolated human antibody, or an antigen-binding portion thereof, of claim 12, wherein the LCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5 and the HCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6. <p>[DC]</p>14. The isolated human antibody, or an antigen-binding portion thereof, of claim 13, wherein the LCVR further has CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7 and the HCVR has a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.",
                     "source":"<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Full Length",
                     "color":"green",
                     "claimReason":"“… comprising a heavy chain comprising ... and a light chain comprising …”",
                     "indClaim":"<p>[IC]</p> 11. An isolated antibody comprising a heavy chain comprising amino acid residues 20 to 446 of SEQ ID NO: 31 and a light chain comprising amino acid residues of 20-237 of SEQ ID NO: 36.",
                     "depClaim":"<p>[DC]</p> None",
                     "source":"<p>Source:</p> US8354509B2, Merck & Co Company: Keytruda® Product"
                  },
                  {  
                     "name":"Nano Bodies",
                     "color":"green"
                  },
                  {  
                     "name":"Constant Region",
                     "color":"green",
                     "claimReason":"“... an IgG1 heavy chain constant ...”",
                     "indClaim":"<p>[IC]</p> 15. An isolated human antibody, or an antigen binding portion thereof, with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.",
                     "depClaim":"<p>[DC]</p> 16. The isolated human antibody of claim 15, which has an IgG1 heavy chain constant region.<p>[DC]</p> 17. The isolated human antibody of claim 15, which has an IgG4 heavy chain constant region.<p>[DC]</p> 18. The isolated human antibody of claim 15, which is a Fab fragment.<p>[DC]</p> 19. The isolated human antibody of claim 15, which is a single chain Fv fragment.",
                     "source":"<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                  }
               ]
            },
            {  
               "name":"Bi-Specific",
               "color":"green",
               "children":[  
                  {  
                     "name":"Normal",
                     "color":"green"
                  },
                  {  
                     "name":"Single Chain",
                     "color":"green",
                     "claimReason":"“… single-chain multi-functional polypeptide comprising …”",
                     "indClaim":"<p>[IC]</p> 1. A single-chain multi-functional polypeptide comprising: <p>(a)</p> a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD19 antigen. <p>(b)</p> a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen, wherein said domains are arranged in the order V L CD19-VHCD19-VHCD3-VLCD3.",
                     "depClaim":"<p>[DC]</p> 2. The polypeptide of claim 1, wherein said two domains are connected by a polypeptide linker.<p>[DC]</p> 3. The polypeptide of claim 1, wherein said first and/or second domain correspond to a VH and VL region from a natural antibody.<p>[DC]</p> 4. The polypeptide of claim 1, wherein said antibody is monoclonal antibody, synthetic antibody, or humanized antibody.<p>[DC]</p> 5. The polypeptide of claim 4, wherein at least one of said domains is a single-chain fragment of the variable region of the antibody.<p>[DC]</p> 6. The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of glycine, alanine, serine residues or combinations thereof.<p>[DC]</p> 7. The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of consecutive copies of an amino acid sequence.<p>[DC]</p> 8. The polypeptide of claim 2, wherein said polypeptide linker comprises 1 to 5 amino acid residues.<p>[DC]</p> 9. The polypeptide of claim 8, wherein said polypeptide linker comprises the amino acid sequence Gly Gly Gly Gly Ser.<p>[DC]</p> 10. The polypeptide of claim 1, wherein <p>(a)</p> said binding site of the first domain has an affinity of at least about 10 -7 M; and/or<p>(b)</p> said binding site of the second domain has an affinity of less than about 10 -7 M.<p>[DC]</p> 11. The polypeptide of claim 1, wherein said polypeptide is a bispecific single-chain antibody.<p>[DC]</p> 12. The polypeptide of claim 1, comprising at least one further domain.<p>[DC]</p> 13. A The polypeptide of claim 12, wherein said further domain is linked by covalent or noncovalent bonds.<p>[DC]</p> 14. The polypeptide of claim 12, wherein said at least one further domain comprises an effector molecule having a conformation suitable for biological activity, capable of sequestering an ion or selective binding to a solid support or to a preselected determinant.<p>[DC]</p> 15. A method for the preparation of a single-chain multi-functional polypeptide comprising: cultivating a cell transfected with a polynucleotide which upon expression encodes the singlechain multi-functional polypeptide of claim 1; and isolating said polypeptide from the cell.",
                     "source":"<p>Source:</p> US7112324B1, Amgen Company: Blincyto® Product"
                  }
               ]
            },
            {  
               "name":"Function",
               "color":"green",
               "children":[  
                  {  
                     "name":"Affinity",
                     "color":"green",
                     "claimReason":"“… dissociates from human TNF with a Kd of 1×10-8 M or less and a Koff rate constant of 1×10-3 s-1 or less …”",
                     "indClaim":"<p>[IC]</p> 1. An isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNF with a Kd of 1×10-8 M or less and a Koff rate constant of 1×10-3 s-1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-7 M or less.",
                     "depClaim":"<p>[DC]</p> 2. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which dissociates from human TNF with a Koff rate constant of 5×10-4 s-1 or less.<p>[DC]</p> 3. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which dissociates from human TNF with a Koff rate constant of 1×10-4 s-1 or less.<p>[DC]</p> 4. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-8 M or less.<p>[DC]</p> 5. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-9 M or less.<p>[DC]</p> 6. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-10 M or less.<p>[DC]</p> 7. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which is a recombinant antibody, or antigen-binding portion thereof.<p>[DC]</p> 8. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which inhibits human TNF-induced expression of ELAM-1 on human umbilical vein endothelial cells.",
                     "source":"<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Cytotoxicity",
                     "color":"green",
                     "claimReason":"“… and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less …”",
                     "indClaim":"<p>[IC]</p> 54. A pharmaceutical composition comprising an isolated human antibody, or antigen-binding portion thereof, which dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less, and a pharmaceutically acceptable carrier, wherein the composition has a form selected from the group consisting of a liquid, a semi-solid dosage form, a solid dosage form, a dispersion, a suspension, a tablet, a pill, a powder, a liposome, and a suppository.",
                     "depClaim":"<p>[DC]</p> None",
                     "source":"<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Binding Inhibition",
                     "color":"green",
                     "claimReason":"“… interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR) …”",
                     "indClaim":"<p>[IC]</p> 1. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the light chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO: 14, wherein the heavy chain and light chain form an antibody that interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1, wherein: <p>a)</p> the heavy chain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 13; and <p>b)</p> the light chain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 14.<p>[DC]</p> 3. The method of claim 2, wherein the heavy chain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 13 and the light chain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 14.",
                     "source":"<p>Source:</p> US8409578B2, Amgen Company: Prolia® Product"
                  },
                  {  
                     "name":"Epitope",
                     "color":"green",
                     "claimReason":"“… antibody which binds to epitope 4D5 within the ErbB2 extracellular domain sequence …”",
                     "indClaim":"<p>[IC]</p> 1. A method for the treatment of a human patient with a malignant progressing tumor or cancer characterized by overexpression of ErbB2 receptor, comprising administering a combination of an intact antibody which binds to epitope 4D5 within the ErbB2 extracellular domain sequence and a taxoid, in the absence of an anthracycline derivative, to the human patient in an amount effective to extend the time to disease progression in said human patient, without increase in overall severe adverse events.",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1 wherein said patient has a malignant tumor.<p>[DC]</p> 3. The method of claim 1 wherein said patient has cancer.<p>[DC]</p> 4. The method of claim 3 wherein said cancer is selected from the group consisting of breast cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.<p>[DC]</p> 5. The method of claim 4 wherein said cancer is breast cancer.<p>[DC]</p> 6. The method of claim 5 wherein said cancer is metastatic breast carcinoma.<p>[DC]</p> 7. The method of claim 1 wherein said antibody is a humanized 4D5 anti-ErbB2 antibody.<p>[DC]</p> 8. The method of claim 1 wherein said taxoid is paclitaxel.<p>[DC]</p> 9. The method of claim 8 wherein the effective amount of said combination is lower than the sum of the effective amounts of said anti-ErbB2 antibody and said taxoid, when administered individually, as single agents.<p>[DC]</p> 10. The method of claim 1 wherein efficacy is further measured by determining the response rate.",
                     "source":"<p>Source:</p> US7846441B1, Genentech Company: Herceptin® Product"
                  }
               ]
            },
            {  
               "name":"Properties",
               "color":"green",
               "children":[  
                  {  
                     "name":"HPLC Properties",
                     "color":"green",
                     "claimReason":"“… wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab …”",
                     "indClaim":"<p>[IC]</p> 1. A composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",
                     "depClaim":"<p>[DC]</p> 2. The composition of claim 1, wherein the acidic species of adalimumab comprise a first acidic region (AR1) and a second acidic region (AR2).<p>[DC]</p> 3. The composition of claim 1, wherein the composition comprises less than 3.8% total acidic species of adalimumab.<p>[DC]</p> 4. The composition of claim 2, wherein the composition comprises 0.8% AR1 and 3.0% AR2.<p>[DC]</p> 5. The composition of claim 1, wherein the composition comprises less than 2.4% total acidic species of adalimumab.<p>[DC]</p> 6. The composition of claim 2, wherein the composition comprises 0.2% AR1 and 2.2% AR2.<p>[DC]</p> 7. The composition of claim 1, wherein the composition comprises 4.7%-8.3% total acidic species of adalimumab.<p>[DC]</p> 8. The composition of claim 7, wherein the composition comprises 4.7% total acidic species of adalimumab.<p>[DC]</p> 9. The composition of claim 7, wherein the composition comprises 5.0% total acidic species of adalimumab.<p>[DC]</p> 10. The composition of claim 7, wherein the composition comprises 5.8% total acidic species of adalimumab.<p>[DC]</p> 11. The composition of claim 7, wherein the composition comprises 6.1% total acidic species of adalimumab.<p>[DC]</p> 12. The composition of claim 7, wherein the composition comprises 6.4% total acidic species of adalimumab.<p>[DC]</p> 13. The composition of claim 7, wherein the composition comprises 8.1% total acidic species of adalimumab.<p>[DC]</p> 14. The composition of claim 7, wherein the composition comprises 8.3% total acidic species of adalimumab.<p>[DC]</p> 15. The composition of claim 2, wherein the composition comprises 0.8%-1.4% AR1.<p>[DC]</p> 16. The composition of claim 2, wherein the composition comprises 3%-9% AR2.17. The composition of claim 2, wherein the composition comprises 0.8% AR1 and 6.4% AR2.<p>[DC]</p> 18. The composition of claim 2, wherein the composition comprises 0.9% AR1 and 9% AR2.<p>[DC]</p> 19. The composition of claim 2, wherein the composition comprises 1.2% AR1 and 7.7% AR2.<p>[DC]</p> 20. The composition of claim 2, wherein the composition comprises 1.2% AR1 and 8.2% AR2.<p>[DC]</p> 21. The composition of claim 2, wherein the composition comprises 1.4% AR1 and 8.4% AR2.<p>[DC]</p> 22. The composition of claim 2, wherein the composition comprises 1.4% AR1 and 8.6% AR2.<p>[DC]</p> 23. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.",
                     "source":"<p>Source:</p> US9334319B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Residue",
                     "color":"green",
                     "claimReason":"“… lysine variant species …”",
                     "indClaim":"<p>[IC]</p> 7. A composition comprising a human anti-TNF antibody, wherein the sum of the lysine variant species having one C-terminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 35%, wherein the lysine variant species include the main peak and peaks that elute at a relative residence time later than the main peak, as detected using weak cation-exchange chromatography, and wherein the human anti-TNF antibody comprises a light chain variable region (LCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region (HCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4.",
                     "depClaim":"<p>[DC]</p> 8. The composition of claim 7, wherein said human anti-TNF antibody is adalimumab.<p>[DC]</p> 9. The composition of claim 8, wherein the sum of the lysine variant species having one C-terminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 40%.<p>[DC]</p> 10. The composition of claim 8, wherein the sum of the lysine variant species having one Cterminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is 40-50%.<p>[DC]</p> 11. The composition of claim 8, wherein the sum of the lysine variant species having one Cterminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 50%.<p>[DC]</p> 12. The composition of claim 8, wherein greater than 25% of the lysine variant species in said composition have one C-terminal lysine (Lys 1).<p>[DC]</p> 13. The composition of claim 8, wherein greater than 30% of the lysine variant species in said composition have one C-terminal lysine (Lys 1).<p>[DC]</p> 14. The composition of claim 7, wherein said composition is lyophilized.<p>[DC]</p> 15. A pharmaceutical formulation comprising the composition of claim 1 and a pharmaceutically acceptable carrier.<p>[DC]</p> 16. A pharmaceutical formulation comprising the composition of claim 7 and a pharmaceutically acceptable carrier.",
                     "source":"<p>Source:</p> US9181337B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Other",
                     "color":"green",
                     "claimReason":"“… mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human …”",
                     "indClaim":"<p>[IC]</p> 15. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, and: <p>(a)</p> binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity: <p>(b)</p> mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human peripheral blood lymphocytes at least about four fold more effectively than the non-human parent antibody; and <p>(c)</p> mediates Antibody Dependent Cellular Cytotoxicity (ADCC) selective for cell types which overexpress p185HER2 at least about two fold more effectively than for cell types which express low levels of p185HER2.",
                     "depClaim":"<p>[DC]</p> 16. The humanized variant of claim 15 which binds the HER2 receptor with an affinity of about 0.82 nM Kd or better affinity.<p>[DC]</p> 17. The humanized variant of claim 16 which binds the HER2 receptor with an affinity of about 0.10 nM Kd.<p>[DC]</p> 18. The humanized variant of claim 15 which inhibits proliferation of SK-BR-3 cells incubated for 96 hr with the antibody.<p>[DC]</p> 19. The humanized variant of claim 18 wherein the antibody inhibits proliferation of SK-BR-3 cells to about 66% of untreated control or greater inhibition.",
                     "source":"<p>Source:</p> US6054297A, Genentech Company: Avastin® Product"
                  }
               ]
            },
            {  
               "name":"Modified Antibody",
               "color":"green",
               "claimReason":"“… the main species HER2 antibody comprising an amino-terminal leader extension …”",
               "indClaim":"<p>[IC]</p> 1. A composition comprising: <p>(a)</p> a main species HER2 antibody that binds to domain II of HER2 and comprises the variable light amino acid sequence in SEQ ID No. 3 and the variable heavy amino acid sequence in SEQ ID No. 4, and <p>(b)</p> the main species HER2 antibody comprising an amino-terminal leader extension, wherein the amino-terminal leader extension comprises VHS-, wherein from 5% to about 15% of the antibody molecules in the composition comprise an aminoterminal leader extension, as quantified by cation exchange analysis.",
               "depClaim":"<p>[DC]</p> 2. The composition of claim 1 wherein the amino-terminal leader extension is on a light chain of the antibody comprising the VHS- extension.<p>[DC]</p> 3. The composition of claim 2 wherein the amino-terminal leader extension is on one or two light chains of the antibody comprising the VHS- extension.<p>[DC]</p> 4. The composition of claim 1 wherein the main species HER2 antibody and the antibody comprising the VHS- extension are both intact antibodies.<p>[DC]</p> 5. The composition of claim 1 wherein the main species HER2 antibody comprises the light chain amino acid sequence in SEQ ID No. 15 and the heavy chain amino acid sequence in SEQ ID No. 16.<p>[DC]</p> 6. The composition of claim 5 further comprising: <p>(a)</p> the main species HER2 antibody comprising a C-terminal lysine residue on one or both heavy chains thereof, <p>(b)</p> a deamidated main species HER2 antibody wherein Asn-386 and/or Asn-391 on one or two heavy chains of the main species HER2 antibody are deamidated, and <p>(c)</p> the main species HER2 antibody with one or more oxidized methionine residues at met-254 of SEQ ID No.16.<p>[DC]</p> 7. The composition of claim 1 wherein the amino-terminal leader extension consists of VHS-.<p>[DC]</p> 8. The composition of claim 1 further comprising a glycosylation variant of the main species HER2 antibody, wherein the glycosylation variant is selected from the group consisting of: <p>(a)</p> the main species HER2 antibody comprising a G1 or G2 oligosaccharide structure attached to an Fc region thereof, <p>(b)</p> the main species HER2 antibody comprising a carbohydrate moiety attached to a light chain thereof, <p>(c)</p> the main species HER2 antibody comprising a non-glycosylated heavy chain, and <p>(d)</p> the main species HER2 antibody with a sialidated oligosaccharide structure attached to an Fc region thereof.<p>[DC]</p> 9. The composition of claim 1 wherein the main species antibody binds to the junction between domains I, II and III of HER2.<p>[DC]</p> 10. A pharmaceutical formulation comprising the composition of claim 1 in a pharmaceutically acceptable carrier.<p>[DC]</p> 11. The pharmaceutical formulation of claim 10 which is sterile.",
               "source":"<p>Source:</p> US7560111B2, Genentech Company: Perjeta® Product"
            },
            {  
               "name":"By Sugar",
               "color":"green",
               "claimReason":"“…  N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F) …”",
               "indClaim":"<p>[IC]</p> 1. A composition comprising adalimumab, wherein more than 25% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).",
               "depClaim":"<p>[DC]</p> 2. The composition of claim 1, wherein 26-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 3. The composition of claim 1, wherein 35-44% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 4. The composition of claim 1, wherein 30-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 5. The composition of claim 1, wherein less than 70% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 6. The composition of claim 5, wherein 49-69% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 7. The composition of claim 5, wherein 55-65% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 8. The composition of claim 1, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media which has been supplemented with a manganese supplement and a galactose supplement.<p>[DC]</p> 9. The composition of claim 1, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media comprising 0.2-100 M of a manganese supplement and 1-100 mM of a galactose supplement.<p>[DC]</p> 10. The composition of claim 9, wherein the cell culture media comprises a hydrolysate based media or a chemically defined media.<p>[DC]</p> 11. The composition of claim 9, wherein the mammalian cell is a CHO cell.<p>[DC]</p> 12. The pharmaceutical composition of claim 11 and a pharmaceutically acceptable carrier comprising a polyalcohol.<p>[DC]</p> 13. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable carrier further comprises polysorbate 80.<p>[DC]</p>  14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is suitable for subcutaneous administration and is formulated in a pre-filled syringe.<p>[DC]</p> 15. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.<p>[DC]</p> 16. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises mannitol.<p>[DC]</p> 17. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises sodium chloride.<p>[DC]</p> 18. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises polysorbate 80.<p>[DC]</p> 19. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises sodium phosphate.<p>[DC]</p> 20. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is suitable for parenteral administration.<p>[DC]</p> 21. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is suitable for subcutaneous administration and is formulated in a pre-filled syringe.",
               "source":"<p>Source:</p> US9255143B2, Abott Biotech Company: Humira® Product"
            },
            {  
               "name":"Crystal",
               "color":"green",
               "claimReason":"“ ... A crystal of an IgG human anti-hTNFalpha antibody comprising two heavy chains each with a molecular weight of about 50 kDa and comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 …”",
               "indClaim":"<p>[IC]</p> 1. A crystal of an IgG human anti-hTNFalpha antibody comprising two heavy chains each with a molecular weight of about 50 kDa and comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, wherein said crystal has a needle morphology with a length of about 2-500 m and an l/d ratio of about 3 to 30.",
               "depClaim":"<p>[DC]</p> 2. The crystal according to claim 1, wherein said antibody is selected from the group consisting of: IgG1, IgG2, IgG3 and IgG4 antibodies.<p>[DC]</p> 3. The crystal according to claim 1, wherein said antibody is an IgG1 antibody.<p>[DC]</p> 4. The crystal according to claim 1, wherein the antibody is adalimumab (D2E7).<p>[DC]</p> 5. A pharmaceutical composition comprising: <p>(a)</p> crystals of an anti-hTNFalpha antibody according to claim 1, and <p>(b)</p> at least one pharmaceutical excipient; wherein the composition is provided as a solid, semisolid or liquid formulation, each formulation containing said antibody in crystalline form.<p>[DC]</p> 6. A pharmaceutical composition comprising: <p>(a)</p> crystals of an anti-hTNFalpha antibody according to claim 1, and <p>(b)</p> at least one pharmaceutical excipient, which embeds or encapsulates crystals of said antibody.<p>[DC]</p> 7. The composition according to claim 5, wherein said composition has an antibody concentration greater than about 1 mg/ml.<p>[DC]</p> 8. The composition according to claim 5, wherein said composition has an antibody concentration greater than about 200 mg/ml.<p>[DC]</p> 9. The composition according to claim 5, wherein said excipient comprises at least one polymeric optionally biodegradable carrier or at least one oil or lipid carrier.<p>[DC]</p> 10. 10. The composition according to claim 9, wherein said polymeric carrier is a polymer selected from one or more of the group consisting of: poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-coglycolic acid) or PLGA, poly (-hydroxybutryate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly (hydroxypropyl) methacrylamide, poly (organo) phosphazene, poly (ortho esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and copolymers thereof.<p>[DC]</p> 11. An injectable liquid composition comprising anti-hTNFalpha antibody crystals according to claim 1 and having an antibody concentration in the range of about 10 to 400 mg/ml.<p>[DC]</p> 12. A crystal slurry comprising anti-hTNFalpha antibody crystals according to claim 1, having an antibody concentration greater than about 100 mg/ml.",
               "source":"<p>Source:</p> US8436149B2, Abott Biotech Company: Humira® Product"
            },
            {  
               "name":"Chimeric",
               "color":"green",
               "claimReason":"“… chimeric antibody comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region …”",
               "indClaim":"<p>[IC]</p> 1. A chimeric antibody comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region, said antibody capable of binding an epitope specific for human tumor necrosis factor TNF, wherein the non-human immunoglobulin variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.",
               "depClaim":"<p>[DC]</p> 2. An immunoassay method for detecting human TNF in a sample, comprising: <p>(a)</p> contacting said sample with an antibody according to claim 1, or a TNF binding fragment thereof, in detectably labeled form; and <p>(b)</p> detecting the binding of the antibody to said TNF.",
               "source":"<p>Source:</p> US6284471B1, Janssen Bio. Company: Remicade® Product"
            }
         ]
      },
      {  
         "name":"Polynucleotide",
         "color":"yellow",
         "children":[  
            {  
               "name":"Vector",
               "color":"yellow"
            },
            {  
               "name":"Sequence",
               "color":"yellow"
            }
         ]
      },
      {  
         "name":"Formulation & Composition",
         "color":"blue",
         "children":[  
            {  
               "name":"Macro",
               "color":"blue",
               "children":[  
                  {  
                     "name":"Dosage Form",
                     "color":"blue"
                  },
                  {  
                     "name":"Pharmaceutical Carrier",
                     "color":"blue"
                  }
               ]
            },
            {  
               "name":"Micro (Concentration, PH, Mass, Conducitivity etc)",
               "color":"blue",
               "children":[  
                  {  
                     "name":"Components",
                     "color":"blue"
                  },
                  {  
                     "name":"Hydrodynamic diameter",
                     "color":"blue"
                  },
                  {  
                     "name":"PH Value",
                     "color":"blue"
                  },
                  {  
                     "name":"Aggregation",
                     "color":"blue"
                  },
                  {  
                     "name":"Multiple Antibodies",
                     "color":"blue"
                  }
               ]
            }
         ]
      },
      {  
         "name":"Treatment",
         "children":[  
            {  
               "name":"Treatment for Condition XYZ",
               "color":"red",
               "children":[  
                  {  
                     "name":"In Vivo",
                     "color":"red"
                  },
                  {  
                     "name":"In Vitro",
                     "color":"red"
                  },
                  {  
                     "name":"Sub-population (Ethnicity, Mutations, Weight, Gender?)",
                     "color":"red",
                     "children":[  
                        {  
                           "name":"Absence of Condition XYZ",
                           "color":"red"
                        },
                        {  
                           "name":"Age",
                           "color":"red"
                        }
                     ]
                  },
                  {  
                     "name":"Second Line Treatment",
                     "color":"red"
                  },
                  {  
                     "name":" Prerequisites",
                     "color":"red"
                  },
                  {  
                     "name":"W/ Formulation",
                     "color":"red"
                  },
                  {  
                     "name":"Treating Signs & Symptons",
                     "color":"red"
                  },
                  {  
                     "name":"Treatment with Side Effects",
                     "color":"red"
                  },
                  {  
                     "name":"Improving effectiveness of Treatment",
                     "color":"red",
                     "children":[  
                        {  
                           "name":"Improving Succes Rate",
                           "color":"red"
                        },
                        {  
                           "name":"Preventing Adverce Events",
                           "color":"red"
                        }
                     ]
                  }
               ]
            },
            {  
               "name":"Mechanism of Action",
               "color":"red"
            },
            {  
               "name":"Depletion of B Cells",
               "color":"red"
            },
            {  
               "name":"Safety",
               "color":"red"
            },
            {  
               "name":"Treatment by which XYZ is achieved",
               "color":"red",
               "children":[  
                  {  
                     "name":"In Vivo",
                     "color":"red"
                  },
                  {  
                     "name":"In Vitro",
                     "color":"red"
                  }
               ]
            },
            {  
               "name":"Regimen",
               "color":"red",
               "children":[  
                  {  
                     "name":"Constant Dose",
                     "color":"red"
                  },
                  {  
                     "name":"Multi-variable Dose",
                     "color":"red"
                  },
                  {  
                     "name":"Dose Dependent on XYZ",
                     "color":"red"
                  },
                  {  
                     "name":"Administration Frequency",
                     "color":"red"
                  }
               ]
            },
            {  
               "name":"Administration in Combination",
               "color":"red"
            },
            {  
               "name":"Inhibiting XYZ",
               "color":"red",
               "children":[  
                  {  
                     "name":"In Vivo",
                     "color":"red"
                  },
                  {  
                     "name":"In Vitro",
                     "color":"red"
                  }
               ]
            },
            {  
               "name":"Vaccine",
               "color":"red"
            }
         ]
      },
      {  
         "name":"Prevention",
         "color":"orange"
      },
      {  
         "name":"Diagnostics",
         "color":"aqua",
         "children":[  
            {  
               "name":"Detecting (e.g. TNF)",
               "color":"aqua",
               "children":[  
                  {  
                     "name":"In Vivo",
                     "color":"aqua"
                  },
                  {  
                     "name":"In Vitro",
                     "color":"aqua"
                  }
               ]
            }
         ]
      },
      {  
         "name":"Competition",
         "color":"navy",
         "children":[  
            {  
               "name":"Cross Competition",
               "color":"navy"
            },
            {  
               "name":"Affinity Competition",
               "color":"navy"
            }
         ]
      },
      {  
         "name":"Drug Delivery Devices",
         "color":"fuchsia",
         "children":[  
            {  
               "name":"Administration Device (General & Treatment specific)",
               "color":"fuchsia",
               "children":[  
                  {  
                     "name":"Components",
                     "color":"fuchsia"
                  },
                  {  
                     "name":"Operation",
                     "color":"fuchsia"
                  }
               ]
            },
            {  
               "name":"Training Device",
               "color":"fuchsia"
            }
         ]
      },
      {  
         "name":"Article of Manufacture",
         "color":"olive"
      },
      {  
         "name":"Methodology",
         "color":"teal",
         "children":[  
            {  
               "name":"Biomarkers",
               "color":"teal",
               "children":[  
                  {  
                     "name":"Efficacy of Treatment",
                     "color":"teal"
                  },
                  {  
                     "name":"Responsiveness",
                     "color":"teal"
                  },
                  {  
                     "name":"Monitoring of XYZ",
                     "color":"teal"
                  },
                  {  
                     "name":"Safety",
                     "color":"teal"
                  }
               ]
            },
            {  
               "name":"Production",
               "color":"teal",
               "children":[  
                  {  
                     "name":"General Method",
                     "color":"teal"
                  },
                  {  
                     "name":"Batch Method",
                     "color":"teal"
                  },
                  {  
                     "name":"Condition XYZ Specific",
                     "color":"teal"
                  },
                  {  
                     "name":"Concentrating",
                     "color":"teal"
                  },
                  {  
                     "name":"Disulfide bond",
                     "color":"teal"
                  },
                  {  
                     "name":"Humanisation",
                     "color":"teal"
                  }
               ]
            },
            {  
               "name":"Modification",
               "color":"teal",
               "children":[  
                  {  
                     "name":"Reducing Impurities",
                     "color":"teal"
                  },
                  {  
                     "name":"Purificiation",
                     "color":"teal",
                     "children":[  
                        {  
                           "name":"Assay for determining functionality",
                           "color":"teal"
                        },
                        {  
                           "name":"Various Methodologies",
                           "color":"teal"
                        }
                     ]
                  },
                  {  
                     "name":"Galactosylation",
                     "color":"teal"
                  },
                  {  
                     "name":"PH",
                     "color":"teal"
                  },
                  {  
                     "name":"Viscosity",
                     "color":"teal"
                  }
               ]
            },
            {  
               "name":"Host Cells",
               "color":"teal",
               "children":[  
                  {  
                     "name":"Enhancing Protein Expression",
                     "color":"teal"
                  },
                  {  
                     "name":"Prolonging Viability",
                     "color":"teal"
                  },
                  {  
                     "name":"Reducing Production of Undesirable XYZ",
                     "color":"teal"
                  },
                  {  
                     "name":"Reducing Consumption of XYZ",
                     "color":"teal"
                  },
                  {  
                     "name":"Capable of Producing XYZ",
                     "color":"teal"
                  },
                  {  
                     "name":"Identified by Deposit  N",
                     "color":"teal"
                  },
                  {  
                     "name":"Glycoengineered",
                     "color":"teal"
                  }
               ]
            }
         ]
      },
      {  
         "name":"Media",
         "color":"maroon",
         "children":[  
            {  
               "name":"Cell Culture Medium",
               "color":"maroon"
            }
         ]
      },
      {  
         "name":"Sequence & Function",
         "color":"silver"
      }
   ]
}
